Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.

British journal of haematology·2026

Same author

Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study.

EJHaem·2026

Same author

Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation: Real-Life Data from Two Centers.

Transplantation and cellular therapy·2026

Same author

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

American journal of hematology·2026

Same author

Rectal Colonization with Multidrug-Resistant Organisms and Subsequent Bloodstream Infections in Hematological Patients Undergoing Cellular Therapies.

Transplantation and cellular therapy·2026

Same author

Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre.

British journal of haematology·2026

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Hematopoietic stem cell therapy for malignant diseases.

Michael Y Shapira¹, Ali Abdul Hai, Panagiotis Tsirigotis

¹Department of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah University Hospital, Jerusalem 91120, Israel. shapiram@hadassah.org.il

Annals of Medicine

|September 14, 2007

Summary

Allogeneic stem cell transplantation (SCT) is now safer and more accessible due to nonmyeloablative conditioning. This advancement has expanded SCT applications for malignant disorders, improving patient outcomes.

More Related Videos

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Related Experiment Videos

Last Updated: Jul 11, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Area of Science:

Hematology
Oncology
Transplantation Medicine

Background:

Allogeneic stem cell transplantation (SCT) has undergone significant evolution over the past 20 years.
Traditional myeloablative conditioning regimens were associated with high toxicity, limiting SCT applicability.

Purpose of the Study:

To review the advancements in allogeneic SCT for malignant disorders.
To highlight the impact of nonmyeloablative conditioning on SCT accessibility and outcomes.

Main Methods:

Review of recent literature on allogeneic stem cell transplantation.
Focus on nonmyeloablative conditioning regimens and their outcomes.
Analysis of changes in patient selection and disease indications for SCT.

Main Results:

Nonmyeloablative conditioning has substantially reduced the toxicity of SCT.
This has broadened the eligibility criteria for SCT to include older patients and those with more comorbidities.
SCT is now a viable option for a wider range of malignant disorders.

Conclusions:

Nonmyeloablative conditioning regimens represent a major breakthrough in allogeneic SCT.
These regimens have made SCT a safer and more widely applicable treatment for malignant diseases.
The evolution of SCT has significantly improved therapeutic options for patients with cancer.